EMBO Journal 2014-12-01

Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.

Maike Jaworski, Ben J Marsland, Jasmine Gehrig, Werner Held, Stéphanie Favre, Sanjiv A Luther, Mai Perroud, Déla Golshayan, Olivier Gaide, Margot Thome

Index: EMBO J. 33(23) , 2765-81, (2014)

Full Text: HTML

Abstract

The protease activity of the paracaspase Malt1 has recently gained interest as a drug target for immunomodulation and the treatment of diffuse large B-cell lymphomas. To address the consequences of Malt1 protease inactivation on the immune response in vivo, we generated knock-in mice expressing a catalytically inactive C472A mutant of Malt1 that conserves its scaffold function. Like Malt1-deficient mice, knock-in mice had strong defects in the activation of lymphocytes, NK and dendritic cells, and the development of B1 and marginal zone B cells and were completely protected against the induction of autoimmune encephalomyelitis. Malt1 inactivation also protected the mice from experimental induction of colitis. However, Malt1 knock-in mice but not Malt1-deficient mice spontaneously developed signs of autoimmune gastritis that correlated with an absence of Treg cells, an accumulation of T cells with an activated phenotype and high serum levels of IgE and IgG1. Thus, removal of the enzymatic activity of Malt1 efficiently dampens the immune response, but favors autoimmunity through impaired Treg development, which could be relevant for therapeutic Malt1-targeting strategies. © 2014 The Authors.